Resinate sustained release dextromethorphan composition
AssigneeCiba-Geigy Corporation
InventorsFranz X. Fischer, Satish C. Khanna
Life of this patent
Estimating the term…
Abstract
A pharmaceutical preparation for controlled, sustained release of dextromethorphan comprising a polystyrene sulfonate resin which has been cross-linked with about 3% to about 10% divinyl benzene, having an average particle size of at least 48 .mu.m and less than 100 .mu.m onto which dextromethorphan has been loaded in a ratio of dextromethorphan hydrobromid to resin of about 1:3 to about 1:10 and at least one pharmaceutically acceptable adjuvant.
Claims20
An antitussive pharmaceutical composition suitable for controlled, sustained release of dextromethorphan comprising (a) a sulfonated polystyrene resin in salt-form crosslinked with about 3% to about 10% by weight (based on the total resin) of cross-linking agent, said resin having an average particle size of at least 40 .mu.m and less than 100 .mu.m, (b) an effective amount of a pharmaceutically acceptable acid addition salt of dextromethorphan, which has been loaded onto said resin in a weight ratio of dextromethorphan-acid addition salt:resin of about 1:5 to about 1:10, and (c) at least one pharmaceutically acceptable adjuvant.
Dependencies are inferred from the claim text.